{"corpus_id":5867328,"paper_sha":"439c0b526f27adb0c4af3f52b7e3de8e747af98a","doi":"10.5144/0256-4947.2015.352","arxiv_id":null,"pmid":26506968,"pmcid":"6074380","mag_id":2474547786,"dblp_id":null,"acl_id":null,"title":"High-volume hemofiltration plus hemoperfusion for hyperlipidemic severe acute pancreatitis: a controlled pilot study","year":2015,"publication_date":"2015-09-01","venue":"Annals of Saudi Medicine","journal":{"name":"Annals of Saudi Medicine","pages":"352 - 358","volume":"35"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle","ClinicalTrial"],"pubmed_pub_types":["Controlled Clinical Trial","Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":29,"citation_count":41,"influential_citation_count":0,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"APACHE","mj":false,"ui":"D018806"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Amylases","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D000681"},{"d":"Biomarkers","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D015415"},{"d":"Blood Pressure","mj":false,"ui":"D001794"},{"d":"Cholesterol","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D002784"},{"d":"Combined Modality Therapy","mj":false,"ui":"D003131"},{"d":"Creatinine","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D003404"},{"d":"Cytokines","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D016207"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Heart Rate","mj":false,"ui":"D006339"},{"d":"Hemofiltration","mj":false,"qs":[{"q":"methods","mj":true,"ui":"Q000379"}],"ui":"D006440"},{"d":"Hemoperfusion","mj":false,"qs":[{"q":"methods","mj":true,"ui":"Q000379"}],"ui":"D006464"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Hyperlipidemias","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"physiopathology","mj":false,"ui":"Q000503"},{"q":"surgery","mj":true,"ui":"Q000601"}],"ui":"D006949"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Pancreatitis","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"},{"q":"physiopathology","mj":false,"ui":"Q000503"},{"q":"surgery","mj":true,"ui":"Q000601"}],"ui":"D010195"},{"d":"Pilot Projects","mj":false,"ui":"D010865"},{"d":"Prospective Studies","mj":false,"ui":"D011446"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Triglycerides","mj":false,"qs":[{"q":"blood","mj":false,"ui":"Q000097"}],"ui":"D014280"}],"chemicals":[{"n":"Biomarkers","ui":"D015415","reg":"0"},{"n":"Cytokines","ui":"D016207","reg":"0"},{"n":"Triglycerides","ui":"D014280","reg":"0"},{"n":"Cholesterol","ui":"D002784","reg":"97C5T2UQ7J"},{"n":"Creatinine","ui":"D003404","reg":"AYI8EX34EU"},{"n":"Amylases","ui":"D000681","reg":"EC 3.2.1.-"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://www.annsaudimed.net/doi/pdf/10.5144/0256-4947.2015.352","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/439c0b526f27adb0c4af3f52b7e3de8e747af98a","s2_open_access_license":"CCBYNCND","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"BACKGROUND AND OBJECTIVES The evidence for high-volume hemofiltration plus hemoperfusion (HVHF&HP) for hyperlipidemic severe acute pancreatitis (HL-SAP) is anecdotal. The purpose of our study was to evaluate the efficacy of HVHF&HP for HL-SAP in a prospective controlled study. DESIGN AND SETTING Prospective controlled pilot study between May 2010 and May 2013 in a hospital intensive care unit. PATIENTS AND METHODS HL-SAP patients chose conventional treatment alone (the control group) or conventional treatment combined with the experimental protocol (the HVHF&HP group) and were prospectively followed in our hospital. APACHE II score, SOFA score, ICU and hospital stay duration, and serum biomarkers were considered endpoints. RESULTS Ten HL-SAP patients accepted conventional treatment alone (the control group) and 10 patients underwent HVHF&HP combined with conventional treatment (the HVHF&HP group). The APACHE II score, SOFA score, systolic blood pressure, diastolic blood pressure, heart rate, serum amylase, and serum creatinine were significantly reduced after the HVHF&HP treatment. The changes in these variables were significantly different between the HVHF&HP and control group at 48 hours after the initiation of treatment. Patients in the HVHF&HP group had a significantly shorter ICU stay (P=.015). The reduction in serum triglyceride and cholesterol in the HVHF&HP group after 2, 6, 12, 24, and 48 hours was greater than the control group. All of the tested serum cytokines were significantly decreased after HVHF&HP treatment (P<.05). However, in patients who underwent conventional treatment alone, there was no significant change in the serum cytokines. CONCLUSION This study suggests that the addition of HVHF&HP to conventional treatment for HL-SAP patients may be superior to conventional treatment alone for the improvement of serum biomarkers and clinical outcomes.","claims":[{"public_id":"cl_4e70f46dcb7e35b942407e9558785cc3","status":"active","text":"Adding high-volume hemofiltration plus hemoperfusion to conventional treatment improved clinical severity scores, vital signs, pancreatic and renal biomarkers, and inflammatory cytokines in hyperlipidemic severe acute pancreatitis.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_4e70f46dcb7e35b942407e9558785cc3"},{"public_id":"cl_b942eaa6ef9eb0b2dc95ba4aa03ed835","status":"active","text":"Changes in APACHE II score, SOFA score, systolic blood pressure, diastolic blood pressure, heart rate, serum amylase, and serum creatinine differed significantly between the intervention and control groups at 48 hours after treatment initiation.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b942eaa6ef9eb0b2dc95ba4aa03ed835"},{"public_id":"cl_a9bff8622b4f89abbab9b68502e1e812","status":"active","text":"Reductions in serum triglyceride and cholesterol were greater with high-volume hemofiltration plus hemoperfusion than with conventional treatment alone across 2 to 48 hours.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_a9bff8622b4f89abbab9b68502e1e812"},{"public_id":"cl_b3afe6452bbea66f2c30853a7264a2b7","status":"active","text":"The intervention group had a significantly shorter ICU stay than the conventional-treatment group.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_b3afe6452bbea66f2c30853a7264a2b7"}],"concepts":[{"public_id":"co_0dbe281dc6f7358480fe3cc1c0b63e6d","status":"active","name":"conventional treatment","description":"Standard non-experimental management used as the comparator in the study.","types":["treatment"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0dbe281dc6f7358480fe3cc1c0b63e6d"},{"public_id":"co_248400ddd220651cb629ecbda4eb9656","status":"active","name":"serum cytokines","description":"Inflammatory signaling proteins measured in blood serum.","types":["biomarker"],"aliases":["cytokines"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_248400ddd220651cb629ecbda4eb9656"},{"public_id":"co_66c47d515de721212e7432d1886e1c71","status":"active","name":"SOFA score","description":"A score used to quantify organ failure severity in critically ill patients.","types":["outcome measure"],"aliases":["Sequential Organ Failure Assessment score"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_66c47d515de721212e7432d1886e1c71"},{"public_id":"co_86fe911c10f63dfb488b07a795cb5095","status":"active","name":"high-volume hemofiltration plus hemoperfusion","description":"An extracorporeal blood purification protocol combining high-volume hemofiltration with hemoperfusion.","types":["treatment"],"aliases":["HVHF&HP","HVHF plus hemoperfusion"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_86fe911c10f63dfb488b07a795cb5095"},{"public_id":"co_8b35b86817f2dbf6894b2f326d86145c","status":"active","name":"hyperlipidemic severe acute pancreatitis","description":"A severe acute pancreatitis subtype associated with hyperlipidemia.","types":["condition"],"aliases":["HL-SAP"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_8b35b86817f2dbf6894b2f326d86145c"},{"public_id":"co_9134bdc43e102bb29d1b7fca246459af","status":"active","name":"intensive care unit stay","description":"The duration of hospitalization in the intensive care unit.","types":["outcome measure"],"aliases":["ICU stay"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9134bdc43e102bb29d1b7fca246459af"},{"public_id":"co_ad07ca197724c7d31de128a70130bf61","status":"active","name":"APACHE II score","description":"A clinical severity score used to assess acute illness severity in intensive care patients.","types":["outcome measure"],"aliases":["Acute Physiology and Chronic Health Evaluation II"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ad07ca197724c7d31de128a70130bf61"},{"public_id":"co_b5976f961ebeba9bc3bf86c90b84b831","status":"active","name":"cholesterol","description":"The concentration of cholesterol measured in blood serum.","types":["biomarker"],"aliases":["serum cholesterol"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b5976f961ebeba9bc3bf86c90b84b831"},{"public_id":"co_b78a105a148ae11fec640cbc5ebadcb6","status":"active","name":"serum triglyceride","description":"The concentration of triglycerides measured in blood serum.","types":["biomarker"],"aliases":["triglyceride"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_b78a105a148ae11fec640cbc5ebadcb6"},{"public_id":"co_d2c521847f14679f365a6d7b59aec607","status":"active","name":"serum biomarkers","description":"Blood-based laboratory markers measured to track disease status and treatment effects.","types":["outcome measure"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d2c521847f14679f365a6d7b59aec607"}],"external_ids":{"DOI":"10.5144/0256-4947.2015.352","ArXiv":null,"PubMed":26506968,"PubMedCentral":"6074380","MAG":2474547786,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://www.annsaudimed.net/doi/pdf/10.5144/0256-4947.2015.352","landing_url":"https://www.semanticscholar.org/paper/439c0b526f27adb0c4af3f52b7e3de8e747af98a","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":638554,"paper_uid":"4645b6b8-7049-4cae-9549-abf691f3ca63","canonical_identity":{"paper_id":638554,"paper_uid":"4645b6b8-7049-4cae-9549-abf691f3ca63","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/5867328"}